ETFs
L
LRMR
Larimar Therapeutics Inc
2.435
+0.315+14.86%Opening13:01 10/20 EDT
OPEN/PREV CLOSE2.120/2.120
TODAY RANGE2.100-2.490
VOL1.06M
MARKET CAP252.95M
52 WEEK RANGE1.915-6.42
AVG VOL (3M)1.31M
% TURNOVER1.02%
TURNOVER--
P/E (TTM)-1.2255
% RANGE18.40%
EPS(TTM)-1.9870
P/E(FORWARD)-1.8305
P/B1.986
BVPS1.226
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP249.77M
SHARES OUTSTANDING103.88M
NEXT EARNINGS11/03-11/09
FREE FLOAT102.57M
LOT SIZE1
EX-DATE05/29/2020
News
Press Releases
Financial Reports
Profile
NASDAQ·38m ago
Tuesday Sector Leaders: Biotechnology, Drugs
NASDAQ·09/30 05:11
Larimar Therapeutics Names John Harlow As President And COO
TipRanks·09/29 20:33
Larimar Therapeutics Appoints New President and COO
TipRanks·09/29 20:15
Larimar Therapeutics appoints John Harlow as COO
Dow Jones·09/29 20:05
*Larimar Therapeutics Appoints John Harlow as Pres and Oper Chief >LRMR
Dow Jones·09/14 21:05
Larimar Therapeutics Coverage Assumed by Leerink Partners at Outperform
Dow Jones·09/14 21:05
Larimar Therapeutics Price Target Announced at $13.00/Share by Leerink Partners
TipRanks·09/14 15:15
Larimar Therapeutics assumed with an Outperform at Leerink
NASDAQ·09/14 13:30
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
TipRanks·09/03 16:32
Larimar’s CTI-1601 Study Update Keeps Friedreich’s Ataxia Catalyst in Play
TipRanks·08/05 14:27
Larimar Therapeutics price target lowered to $11 from $12 at Wedbush
Benzinga·08/05 13:24
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11
Same Industry
Name/Symbol
Change%
Price